Form 4: Celcuity Director Polly A. Murphy Receives Significant Stock Option Grants

Celcuity Inc. Director Polly A. Murphy was granted a total of 36,098 stock options across three tranches on June 24, 2024, all of which are 100% vested and held indirectly through a family trust.

Summary

• Polly A. Murphy, a Director of Celcuity Inc. (CELC), received grants of stock options on June 24, 2024.
• The grants include 16,300 stock options with an exercise price of $8.31, expiring on September 12, 2032.
• An additional 11,645 stock options were granted with an exercise price of $9.58, expiring on May 15, 2033.
• A third grant consisted of 8,153 stock options with an exercise price of $14.83, expiring on June 4, 2034.
• All 36,098 stock options granted are 100% vested upon grant.
• The options are beneficially owned indirectly by Polly A. Murphy through a trust, where she and her spouse serve as trustees and beneficiaries.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While stock option grants can lead to dilution, they primarily serve to align the interests of the director with those of the shareholders, which is generally viewed favorably. It is a routine compensation disclosure rather than a performance update.

Positives

• The grant of stock options to a director aligns management and director incentives with shareholder interests, as the options gain value if the company's stock price increases.
• All granted options are 100% vested immediately, providing immediate equity exposure and incentive.

Negatives

• The issuance of new stock options can lead to potential dilution for existing shareholders if exercised, although this is a standard form of executive and director compensation.

Future Outlook

This SEC Form 4 filing is a disclosure of an insider transaction and does not contain forward-looking statements or guidance regarding the company's future financial performance or strategic outlook.

Industry Context

This filing is a routine disclosure of director compensation in the form of stock options, common across publicly traded companies in all industries, including the biotechnology or pharmaceutical sector where Celcuity Inc. operates. It reflects standard practices for aligning director interests with company performance.

Comparison to Industry Standards

• The granting of stock options as part of director compensation is a common practice across publicly traded companies, including those in the biotech and healthcare sectors, such as Celcuity Inc. This aligns with typical compensation structures seen in companies like Guardant Health (GH), Exact Sciences (EXAS), or Natera (NTRA), which also utilize equity-based incentives for their leadership.
• The immediate 100% vesting of these options is a less common but not unheard-of practice for director grants, often used to provide immediate alignment and reward for board service, contrasting with multi-year vesting schedules typical for employee stock options.

Related Party Transactions

• The transaction involves the grant of stock options to Polly A. Murphy, a Director of Celcuity Inc., which is a standard form of compensation for an insider.

Stakeholder Impact

• Shareholders: Potential for minor dilution if options are exercised, but also improved alignment of director's interests with stock performance.
• Employees: No direct impact mentioned, but reflects standard compensation practices for leadership.

Key Dates

Keywords

Celcuity Inc., CELC, Stock Options, SEC Form 4, Insider Transaction, Director Compensation, Equity Grant, Beneficial Ownership